CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis

Background: Disease activity in the first years after a diagnosis of relapsing-remitting multiple sclerosis (RRMS) is a negative prognostic factor for long-term disability. Markers of both clinical and radiological responses to disease-modifying therapies (DMTs) are advocated. Objective: The objecti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Therapeutic advances in neurological disorders Ročník 15; s. 17562864221092124
Hlavní autoři: Marastoni, Damiano, Pisani, Anna I., Schiavi, Gianmarco, Mazziotti, Valentina, Castellaro, Marco, Tamanti, Agnese, Bosello, Francesca, Crescenzo, Francesco, Ricciardi, Giuseppe K., Montemezzi, Stefania, Pizzini, Francesca B., Calabrese, Massimiliano
Médium: Journal Article
Jazyk:angličtina
Vydáno: London, England SAGE Publications 2022
SAGE PUBLICATIONS, INC
SAGE Publishing
Témata:
APRIL protein
CD163 antigen
Cerebrospinal fluid
Chemokines
CXCL12 protein
CXCL13 protein
Demography
Diagnosis
Inflammation
Interleukin 12
Ligands
Lymphocytes B
Magnetic resonance imaging
Multiple sclerosis
Original Research
Osteopontin
Patients
Substantia alba
Substantia grisea
Tumor necrosis factor
Tumor necrosis factor-TNF
Tumors
γ-Interferon
relapsing multiple sclerosis
osteopontin
disease activity
cytokines
dimethyl fumarate
chemokines
TNF
ISSN:1756-2864, 1756-2856, 1756-2864
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Background: Disease activity in the first years after a diagnosis of relapsing-remitting multiple sclerosis (RRMS) is a negative prognostic factor for long-term disability. Markers of both clinical and radiological responses to disease-modifying therapies (DMTs) are advocated. Objective: The objective of this study is to estimate the value of cerebrospinal fluid (CSF) inflammatory markers at the time of diagnosis in predicting the disease activity in treatment-naïve multiple sclerosis (MS) patients exposed to dimethyl fumarate (DMF). Methods: In total, 48 RRMS patients (31 females/17 males) treated with DMF after the diagnosis were included in this 2-year longitudinal study. All patients underwent a CSF examination, regular clinical and 3T magnetic resonance imaging (MRI) scans that included the assessment of white matter (WM) lesions, cortical lesions (CLs) and global cortical thickness. CSF levels of 10 pro-inflammatory markers – CXCL13 [chemokine (C-X-C motif) ligand 13 or B lymphocyte chemoattractant], CXCL12 (stromal cell-derived factor or C-X-C motif chemokine 12), tumour necrosis factor (TNF), APRIL (a proliferation-inducing ligand, or tumour necrosis factor ligand superfamily member 13), LIGHT (tumour necrosis factor ligand superfamily member 14 or tumour necrosis factor superfamily member 14), interferon (IFN) gamma, interleukin 12 (IL-12), osteopontin, sCD163 [soluble-CD163 (cluster of differentiation 163)] and Chitinase3-like1 – were assessed using immune-assay multiplex techniques. The combined three-domain status of ‘no evidence of disease activity’ (NEDA-3) was defined by no relapses, no disability worsening and no MRI activity, including CLs. Results: Twenty patients (42%) reached the NEDA-3 status; patients with disease activity showed higher CSF TNF (p = 0.009), osteopontin (p = 0.005), CXCL12 (p = 0.037), CXCL13 (p = 0.040) and IFN gamma levels (p = 0.019) compared with NEDA-3 patients. After applying a random forest approach, TNF and osteopontin revealed the most important variables associated with the NEDA-3 status. Six molecules that emerged at the random forest approach were added in a multivariate regression model with demographic, clinical and MRI measures of WM and grey matter damage as independent variables. TNF levels confirmed to be associated with the absence of disease activity: odds ratio (OR) = 0.25, CI% = 0.04–0.77. Conclusion: CSF inflammatory markers may provide prognostic information in predicting disease activity in the first years after DMF initiation. CSF TNF levels are a possible candidate in predicting treatment response, in addition to clinical, demographic and MRI variables.
AbstractList Background: Disease activity in the first years after a diagnosis of relapsing-remitting multiple sclerosis (RRMS) is a negative prognostic factor for long-term disability. Markers of both clinical and radiological responses to disease-modifying therapies (DMTs) are advocated. Objective: The objective of this study is to estimate the value of cerebrospinal fluid (CSF) inflammatory markers at the time of diagnosis in predicting the disease activity in treatment-naïve multiple sclerosis (MS) patients exposed to dimethyl fumarate (DMF). Methods: In total, 48 RRMS patients (31 females/17 males) treated with DMF after the diagnosis were included in this 2-year longitudinal study. All patients underwent a CSF examination, regular clinical and 3T magnetic resonance imaging (MRI) scans that included the assessment of white matter (WM) lesions, cortical lesions (CLs) and global cortical thickness. CSF levels of 10 pro-inflammatory markers – CXCL13 [chemokine (C-X-C motif) ligand 13 or B lymphocyte chemoattractant], CXCL12 (stromal cell-derived factor or C-X-C motif chemokine 12), tumour necrosis factor (TNF), APRIL (a proliferation-inducing ligand, or tumour necrosis factor ligand superfamily member 13), LIGHT (tumour necrosis factor ligand superfamily member 14 or tumour necrosis factor superfamily member 14), interferon (IFN) gamma, interleukin 12 (IL-12), osteopontin, sCD163 [soluble-CD163 (cluster of differentiation 163)] and Chitinase3-like1 – were assessed using immune-assay multiplex techniques. The combined three-domain status of ‘no evidence of disease activity’ (NEDA-3) was defined by no relapses, no disability worsening and no MRI activity, including CLs. Results: Twenty patients (42%) reached the NEDA-3 status; patients with disease activity showed higher CSF TNF (p = 0.009), osteopontin (p = 0.005), CXCL12 (p = 0.037), CXCL13 (p = 0.040) and IFN gamma levels (p = 0.019) compared with NEDA-3 patients. After applying a random forest approach, TNF and osteopontin revealed the most important variables associated with the NEDA-3 status. Six molecules that emerged at the random forest approach were added in a multivariate regression model with demographic, clinical and MRI measures of WM and grey matter damage as independent variables. TNF levels confirmed to be associated with the absence of disease activity: odds ratio (OR) = 0.25, CI% = 0.04–0.77. Conclusion: CSF inflammatory markers may provide prognostic information in predicting disease activity in the first years after DMF initiation. CSF TNF levels are a possible candidate in predicting treatment response, in addition to clinical, demographic and MRI variables.
Disease activity in the first years after a diagnosis of relapsing-remitting multiple sclerosis (RRMS) is a negative prognostic factor for long-term disability. Markers of both clinical and radiological responses to disease-modifying therapies (DMTs) are advocated.BackgroundDisease activity in the first years after a diagnosis of relapsing-remitting multiple sclerosis (RRMS) is a negative prognostic factor for long-term disability. Markers of both clinical and radiological responses to disease-modifying therapies (DMTs) are advocated.The objective of this study is to estimate the value of cerebrospinal fluid (CSF) inflammatory markers at the time of diagnosis in predicting the disease activity in treatment-naïve multiple sclerosis (MS) patients exposed to dimethyl fumarate (DMF).ObjectiveThe objective of this study is to estimate the value of cerebrospinal fluid (CSF) inflammatory markers at the time of diagnosis in predicting the disease activity in treatment-naïve multiple sclerosis (MS) patients exposed to dimethyl fumarate (DMF).In total, 48 RRMS patients (31 females/17 males) treated with DMF after the diagnosis were included in this 2-year longitudinal study. All patients underwent a CSF examination, regular clinical and 3T magnetic resonance imaging (MRI) scans that included the assessment of white matter (WM) lesions, cortical lesions (CLs) and global cortical thickness. CSF levels of 10 pro-inflammatory markers - CXCL13 [chemokine (C-X-C motif) ligand 13 or B lymphocyte chemoattractant], CXCL12 (stromal cell-derived factor or C-X-C motif chemokine 12), tumour necrosis factor (TNF), APRIL (a proliferation-inducing ligand, or tumour necrosis factor ligand superfamily member 13), LIGHT (tumour necrosis factor ligand superfamily member 14 or tumour necrosis factor superfamily member 14), interferon (IFN) gamma, interleukin 12 (IL-12), osteopontin, sCD163 [soluble-CD163 (cluster of differentiation 163)] and Chitinase3-like1 - were assessed using immune-assay multiplex techniques. The combined three-domain status of 'no evidence of disease activity' (NEDA-3) was defined by no relapses, no disability worsening and no MRI activity, including CLs.MethodsIn total, 48 RRMS patients (31 females/17 males) treated with DMF after the diagnosis were included in this 2-year longitudinal study. All patients underwent a CSF examination, regular clinical and 3T magnetic resonance imaging (MRI) scans that included the assessment of white matter (WM) lesions, cortical lesions (CLs) and global cortical thickness. CSF levels of 10 pro-inflammatory markers - CXCL13 [chemokine (C-X-C motif) ligand 13 or B lymphocyte chemoattractant], CXCL12 (stromal cell-derived factor or C-X-C motif chemokine 12), tumour necrosis factor (TNF), APRIL (a proliferation-inducing ligand, or tumour necrosis factor ligand superfamily member 13), LIGHT (tumour necrosis factor ligand superfamily member 14 or tumour necrosis factor superfamily member 14), interferon (IFN) gamma, interleukin 12 (IL-12), osteopontin, sCD163 [soluble-CD163 (cluster of differentiation 163)] and Chitinase3-like1 - were assessed using immune-assay multiplex techniques. The combined three-domain status of 'no evidence of disease activity' (NEDA-3) was defined by no relapses, no disability worsening and no MRI activity, including CLs.Twenty patients (42%) reached the NEDA-3 status; patients with disease activity showed higher CSF TNF (p = 0.009), osteopontin (p = 0.005), CXCL12 (p = 0.037), CXCL13 (p = 0.040) and IFN gamma levels (p = 0.019) compared with NEDA-3 patients. After applying a random forest approach, TNF and osteopontin revealed the most important variables associated with the NEDA-3 status. Six molecules that emerged at the random forest approach were added in a multivariate regression model with demographic, clinical and MRI measures of WM and grey matter damage as independent variables. TNF levels confirmed to be associated with the absence of disease activity: odds ratio (OR) = 0.25, CI% = 0.04-0.77.ResultsTwenty patients (42%) reached the NEDA-3 status; patients with disease activity showed higher CSF TNF (p = 0.009), osteopontin (p = 0.005), CXCL12 (p = 0.037), CXCL13 (p = 0.040) and IFN gamma levels (p = 0.019) compared with NEDA-3 patients. After applying a random forest approach, TNF and osteopontin revealed the most important variables associated with the NEDA-3 status. Six molecules that emerged at the random forest approach were added in a multivariate regression model with demographic, clinical and MRI measures of WM and grey matter damage as independent variables. TNF levels confirmed to be associated with the absence of disease activity: odds ratio (OR) = 0.25, CI% = 0.04-0.77.CSF inflammatory markers may provide prognostic information in predicting disease activity in the first years after DMF initiation. CSF TNF levels are a possible candidate in predicting treatment response, in addition to clinical, demographic and MRI variables.ConclusionCSF inflammatory markers may provide prognostic information in predicting disease activity in the first years after DMF initiation. CSF TNF levels are a possible candidate in predicting treatment response, in addition to clinical, demographic and MRI variables.
Background: Disease activity in the first years after a diagnosis of relapsing-remitting multiple sclerosis (RRMS) is a negative prognostic factor for long-term disability. Markers of both clinical and radiological responses to disease-modifying therapies (DMTs) are advocated. Objective: The objective of this study is to estimate the value of cerebrospinal fluid (CSF) inflammatory markers at the time of diagnosis in predicting the disease activity in treatment-naïve multiple sclerosis (MS) patients exposed to dimethyl fumarate (DMF). Methods: In total, 48 RRMS patients (31 females/17 males) treated with DMF after the diagnosis were included in this 2-year longitudinal study. All patients underwent a CSF examination, regular clinical and 3T magnetic resonance imaging (MRI) scans that included the assessment of white matter (WM) lesions, cortical lesions (CLs) and global cortical thickness. CSF levels of 10 pro-inflammatory markers – CXCL13 [chemokine (C-X-C motif) ligand 13 or B lymphocyte chemoattractant], CXCL12 (stromal cell-derived factor or C-X-C motif chemokine 12), tumour necrosis factor (TNF), APRIL (a proliferation-inducing ligand, or tumour necrosis factor ligand superfamily member 13), LIGHT (tumour necrosis factor ligand superfamily member 14 or tumour necrosis factor superfamily member 14), interferon (IFN) gamma, interleukin 12 (IL-12), osteopontin, sCD163 [soluble-CD163 (cluster of differentiation 163)] and Chitinase3-like1 – were assessed using immune-assay multiplex techniques. The combined three-domain status of ‘no evidence of disease activity’ (NEDA-3) was defined by no relapses, no disability worsening and no MRI activity, including CLs. Results: Twenty patients (42%) reached the NEDA-3 status; patients with disease activity showed higher CSF TNF (p = 0.009), osteopontin (p = 0.005), CXCL12 (p = 0.037), CXCL13 (p = 0.040) and IFN gamma levels (p = 0.019) compared with NEDA-3 patients. After applying a random forest approach, TNF and osteopontin revealed the most important variables associated with the NEDA-3 status. Six molecules that emerged at the random forest approach were added in a multivariate regression model with demographic, clinical and MRI measures of WM and grey matter damage as independent variables. TNF levels confirmed to be associated with the absence of disease activity: odds ratio (OR) = 0.25, CI% = 0.04–0.77. Conclusion: CSF inflammatory markers may provide prognostic information in predicting disease activity in the first years after DMF initiation. CSF TNF levels are a possible candidate in predicting treatment response, in addition to clinical, demographic and MRI variables.
Author Tamanti, Agnese
Montemezzi, Stefania
Bosello, Francesca
Ricciardi, Giuseppe K.
Marastoni, Damiano
Pisani, Anna I.
Mazziotti, Valentina
Calabrese, Massimiliano
Castellaro, Marco
Schiavi, Gianmarco
Crescenzo, Francesco
Pizzini, Francesca B.
Author_xml – sequence: 1
  givenname: Damiano
  orcidid: 0000-0003-0358-9431
  surname: Marastoni
  fullname: Marastoni, Damiano
  organization: Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
– sequence: 2
  givenname: Anna I.
  surname: Pisani
  fullname: Pisani, Anna I.
  organization: Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
– sequence: 3
  givenname: Gianmarco
  surname: Schiavi
  fullname: Schiavi, Gianmarco
  organization: Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
– sequence: 4
  givenname: Valentina
  surname: Mazziotti
  fullname: Mazziotti, Valentina
  organization: Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
– sequence: 5
  givenname: Marco
  surname: Castellaro
  fullname: Castellaro, Marco
  organization: Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
– sequence: 6
  givenname: Agnese
  surname: Tamanti
  fullname: Tamanti, Agnese
  organization: Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
– sequence: 7
  givenname: Francesca
  surname: Bosello
  fullname: Bosello, Francesca
  organization: Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, Ocular Immunology and Neuroophthalmology Service, AOUI-University of Verona, Verona, Italy
– sequence: 8
  givenname: Francesco
  surname: Crescenzo
  fullname: Crescenzo, Francesco
  organization: Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
– sequence: 9
  givenname: Giuseppe K.
  surname: Ricciardi
  fullname: Ricciardi, Giuseppe K.
  organization: Neuroradiology & Radiology Units, Integrated University Hospital of Verona, Verona, Italy
– sequence: 10
  givenname: Stefania
  surname: Montemezzi
  fullname: Montemezzi, Stefania
  organization: Neuroradiology & Radiology Units, Integrated University Hospital of Verona, Verona, Italy
– sequence: 11
  givenname: Francesca B.
  surname: Pizzini
  fullname: Pizzini, Francesca B.
  organization: Radiology, Department of Diagnostic and Public Health, Integrated University Hospital of Verona, Verona, Italy
– sequence: 12
  givenname: Massimiliano
  surname: Calabrese
  fullname: Calabrese, Massimiliano
  email: massimiliano.calabrese@univr.it
  organization: Neurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico ‘G.B. Rossi’ Borgo Roma, Piazzale L. A. Scuro, 10, 37134 Verona, Italy
BookMark eNp9kk9vEzEQxVeoiLaBD8DNEhcuKf67Xl-QUNTQShUcKGfLsWcTB2cdbG9Rvj1eUlFaBCdb4_d-ejOe8-ZkiAM0zWuCLwiR8h2RoqVdyyklWFFC-bPmbKrNp-LJH_fT5jznLcYtlRy_aE6ZkEKoVp013xZfluj20xKZwaGYC8R9HIofUIA7CBnZmBIEUwD98GWDygZQglw1GVCJyPkdlM0hoH7cmTTJqhVMCge0G0Px-wAo2wApZp9fNs97EzK8uj9nzdfl5e3ian7z-eP14sPN3Aqsyly2zIIFLgWlrG8NZa4zdiUBeNeq3nGgqheq79reYUGEk4xTxazFq1XH2IrNmusj10Wz1fvka7SDjsbrX4WY1tqk4mssDc5VH6kI4ThT1ijHZdsr0QthDe4q6_2RtR9XO3AWhpJMeAR9_DL4jV7HO13_o-MMV8Dbe0CK30fIRe98thCCGSCOWdO2I5xzoibpmyfSbRzTUEelqZSKiFbV_mYNOapsHWpO0P8OQ7Ce1kL_tRbVI594rC-m-Dhl9uG_zoujM5s1POT5t-EnWorKUg
CitedBy_id crossref_primary_10_1212_NXI_0000000000200265
crossref_primary_10_1016_j_cca_2023_117471
crossref_primary_10_3390_biomedicines10082041
crossref_primary_10_1002_ana_26913
crossref_primary_10_1007_s00415_025_13321_8
crossref_primary_10_3389_fimmu_2023_1111719
crossref_primary_10_3389_fimmu_2024_1343892
crossref_primary_10_1002_ana_27024
crossref_primary_10_3390_biomedicines11010178
crossref_primary_10_3390_ijms26094455
Cites_doi 10.1212/WNL.33.11.1444
10.1177/1352458517703193
10.1016/S1474-4422(12)70230-2
10.1212/WNL.0b013e3181c47cc2
10.1001/jamaneurol.2019.2399
10.1212/NXI.0000000000001083
10.1186/s40478-020-00938-1
10.1016/S1474-4422(19)30391-6
10.1212/NXI.0000000000001059.
10.1177/1352458513498128
10.1186/s12974-019-1650-x
10.3390/cells9102290
10.1038/ni1415
10.1212/WNL.0000000000000560
10.1177/1352458515616701
10.1212/01.wnl.0000435551.90824.d0
10.1056/NEJMoa1114287
10.1001/jamaneurol.2018.4905
10.1093/brain/aws246
10.1212/WNL.0000000000007032
10.1016/S1474-4422(17)30470-2
10.1126/science.1062960
10.1001/jamaneurol.2014.3537
10.1038/s41582-019-0170-8
10.1002/ana.25786
10.1002/ana.25197
10.1212/NXI.0000000000001082.
10.1006/cimm.2000.1706
10.1016/j.neuroimage.2012.01.021
10.1016/j.nic.2016.12.009
10.1212/WNL.0000000000005772
10.1212/WNL.0000000000005685
10.1093/brain/awaa251
10.1093/brain/awab033
10.1002/ana.410130302
10.3389/fncel.2020.00190
10.1016/j.jneuroim.2015.04.011
10.1007/s00401-021-02274-7
10.1093/brain/awq386
10.1111/ene.13272
10.3390/cells10071712
10.1016/S1474-4422(21)00095-8
10.1016/S0140-6736(18)30481-1
ContentType Journal Article
Copyright The Author(s), 2022
The Author(s), 2022. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s), 2022.
The Author(s), 2022 2022 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
Copyright_xml – notice: The Author(s), 2022
– notice: The Author(s), 2022. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s), 2022.
– notice: The Author(s), 2022 2022 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
DBID AFRWT
AAYXX
CITATION
3V.
7TK
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
7X8
5PM
DOA
DOI 10.1177/17562864221092124
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Psychology
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-2864
ExternalDocumentID oai_doaj_org_article_eddcc01d735d439ca9d476f95f55ca08
PMC9218430
10_1177_17562864221092124
10.1177_17562864221092124
GrantInformation_xml – fundername: Italian Ministry of Health
  grantid: GR-2013-02-355322
– fundername: ;
  grantid: GR-2013-02-355322
GroupedDBID ---
-TM
01A
0R~
123
18M
29Q
4.4
53G
54M
5VS
7X7
8FI
8FJ
AABMB
AADUE
AAKDD
AAQDB
AARDL
AARIX
AASGM
ABAWP
ABEIX
ABFWQ
ABJIS
ABKRH
ABNCE
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACOFE
ACROE
ACRPL
ADBBV
ADEBD
ADNMO
ADOGD
ADYCS
ADZZY
AENEX
AEQLS
AERKM
AEUHG
AEWDL
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AFWMB
AGNHF
AGQPQ
AHHFK
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AUTPY
AUVAJ
AVWKF
AYAKG
AZFZN
B8M
BAWUL
BCNDV
BDDNI
BENPR
BKSCU
BPHCQ
BSEHC
BVXVI
CAG
CCPQU
CDWPY
CFDXU
COF
CS3
DC-
DC.
DIK
DOPDO
E3Z
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
H13
HMCUK
HVGLF
HYE
HZ~
J8X
K.F
N9A
O9-
OK1
P.B
PHGZM
PHGZT
PIMPY
PQQKQ
PSYQQ
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
AFFHD
CITATION
3V.
7TK
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c509t-763cece475223f6a23d8acb7ee4869fd4e29f59f86fd0515d734293cc0bb833b3
IEDL.DBID DOA
ISICitedReferencesCount 11
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000814448400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1756-2864
1756-2856
IngestDate Fri Oct 03 12:37:28 EDT 2025
Tue Nov 04 01:54:52 EST 2025
Sun Nov 09 13:55:35 EST 2025
Tue Oct 07 06:49:24 EDT 2025
Tue Nov 18 21:55:29 EST 2025
Sat Nov 29 08:16:57 EST 2025
Tue Jun 17 22:37:24 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords relapsing multiple sclerosis
osteopontin
disease activity
cytokines
dimethyl fumarate
chemokines
TNF
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c509t-763cece475223f6a23d8acb7ee4869fd4e29f59f86fd0515d734293cc0bb833b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Damiano Marastoni and Anna I. Pisani equally contributed to the study.
ORCID 0000-0003-0358-9431
OpenAccessLink https://doaj.org/article/eddcc01d735d439ca9d476f95f55ca08
PMID 35755969
PQID 2779156983
PQPubID 4450847
ParticipantIDs doaj_primary_oai_doaj_org_article_eddcc01d735d439ca9d476f95f55ca08
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9218430
proquest_miscellaneous_2681444190
proquest_journals_2779156983
crossref_primary_10_1177_17562864221092124
crossref_citationtrail_10_1177_17562864221092124
sage_journals_10_1177_17562864221092124
PublicationCentury 2000
PublicationDate 2022-00-00
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – year: 2022
  text: 2022-00-00
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: London
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in neurological disorders
PublicationYear 2022
Publisher SAGE Publications
SAGE PUBLICATIONS, INC
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: SAGE PUBLICATIONS, INC
– name: SAGE Publishing
References Kuhle, Kropshofer, Haering 2019; 92
Rossi, Motta, Studer 2014; 20
Thompson, Baranzini, Geurts 2018; 391
Ferraro, Galli, Vitetta 2015; 283
Scalfari, Romualdi, Nicholas 2018; 90
Filippi, Preziosa, Copetti 2013; 81
Fresegna, Bullitta, Musella 2020 2290; 9
James, Schalks, Browne 2020; 8
Calabrese, Castellaro 2017; 27
Poser, Paty, Scheinberg 1983; 13
Kappos, De Stefano, Freedman 2016; 22
Amato, Fonderico, Portaccio 2020; 143
Hur, Youssef, Haws 2007; 8
Thompson, Banwell, Barkhof 2018; 17
Wattjes, Ciccarelli, Reich 2021 2021; 20
Geurts, Calabrese, Fisher 2012; 11
Picon, Jayaraman, James 2021; 141
Harding, Williams, Willis 2019; 76
Giovannoni, Tomic, Bright 2017; 23
Havrdova, Giovannoni, Gold 2017; 24
Teunissen, Petzold, Bennett 2009; 73
Derfuss, Mehling, Papadopoulou 2020; 19
Magliozzi, Pezzini, Pucci 2021 1712; 10
Chabas, Baranzini, Mitchell 2001; 294
Kurtzke 1983; 33
Marastoni, Magliozzi, Bolzan 2021; 8
Calabrese, Poretto, Favaretto 2012; 135
Rotstein, Healy, Malik 2015; 72
Prosperini, Lucchini, Haggiag 2018; 91
Haider, Prados, Chung 2021; 144
Gold, Kappos, Arnold 2012; 367
Lublin, Reingold, Cohen 2014; 83
Rotstein, Montalban 2019; 15
Magliozzi, Howell, Durrenberger 2019; 16
Absinta, Sati, Masuzzo 2019; 76
Suvannavejh, Lee, Padilla 2000; 205
Magliozzi, Scalfari, Pisani 2020; 88
Comabella, Sastre-Garriga, Borras 2021
Prosperini, Ruggieri, Haggiag 2021
Magliozzi, Howell, Nicholas 2018; 83
Veroni, Serafini, Rosicarelli 2020; 14
Linker, Lee, Ryan 2011; 134
Fischl 2012; 62
bibr6-17562864221092124
bibr19-17562864221092124
bibr9-17562864221092124
bibr24-17562864221092124
bibr11-17562864221092124
bibr29-17562864221092124
bibr39-17562864221092124
bibr37-17562864221092124
bibr21-17562864221092124
bibr27-17562864221092124
bibr1-17562864221092124
bibr34-17562864221092124
bibr41-17562864221092124
bibr14-17562864221092124
bibr31-17562864221092124
bibr5-17562864221092124
bibr32-17562864221092124
bibr42-17562864221092124
bibr8-17562864221092124
bibr35-17562864221092124
bibr18-17562864221092124
bibr28-17562864221092124
bibr38-17562864221092124
bibr25-17562864221092124
bibr15-17562864221092124
bibr2-17562864221092124
bibr12-17562864221092124
bibr22-17562864221092124
bibr7-17562864221092124
bibr4-17562864221092124
bibr10-17562864221092124
bibr23-17562864221092124
bibr17-17562864221092124
bibr20-17562864221092124
bibr13-17562864221092124
bibr33-17562864221092124
bibr36-17562864221092124
bibr26-17562864221092124
bibr43-17562864221092124
bibr16-17562864221092124
bibr40-17562864221092124
bibr30-17562864221092124
bibr3-17562864221092124
References_xml – volume: 24
  start-page: 726
  year: 2017
  end-page: 733
  article-title: Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
  publication-title: Eur J Neurol
– volume: 90
  year: 2018
  article-title: The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis
  publication-title: Neurology
– volume: 8
  start-page: 66
  year: 2020
  article-title: Persistent elevation of intrathecal pro-inflammatory cytokines leads to multiple sclerosis-like cortical demyelination and neurodegeneration
  publication-title: Acta Neuropathol Commun
– volume: 135
  start-page: 2952
  year: 2012
  end-page: 2961
  article-title: Cortical lesion load associates with progression of disability in multiple sclerosis
  publication-title: Brain
– volume: 72
  start-page: 152
  year: 2015
  end-page: 158
  article-title: Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort
  publication-title: JAMA Neurol
– volume: 88
  start-page: 562
  year: 2020
  end-page: 573
  article-title: The CSF profile linked to cortical damage predicts multiple sclerosis activity
  publication-title: Ann Neurol
– volume: 22
  start-page: 1297
  year: 2016
  end-page: 1305
  article-title: Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis
  publication-title: Mult Scler
– volume: 62
  start-page: 774
  year: 2012
  end-page: 781
  article-title: FreeSurfer
  publication-title: NeuroImage
– volume: 8
  start-page: e1083
  year: 2021
  article-title: CSF Levels of CXCL12 and osteopontin as early markers of primary progressive multiple sclerosis
  publication-title: Neurol Neuroimmunol Neuroinflammation
– year: 2021
  article-title: CSF chitinase 3-like 2 is associated with long-term disability progression in patients with progressive multiple sclerosis
  publication-title: Neurol Neuroimmunol Neuroinflammation
– volume: 81
  start-page: 1759
  year: 2013
  end-page: 1767
  article-title: Gray matter damage predicts the accumulation of disability 13 years later in MS
  publication-title: Neurology
– volume: 8
  start-page: 74
  year: 2007
  end-page: 83
  article-title: Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells
  publication-title: Nat Immunol
– volume: 76
  start-page: 536
  year: 2019
  end-page: 541
  article-title: Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis
  publication-title: JAMA Neurol
– volume: 16
  start-page: 251
  year: 2019
  article-title: Meningeal inflammation changes the balance of TNF signalling in cortical grey matter in multiple sclerosis
  publication-title: J Neuroinflammation
– year: 2021
  article-title: Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis
  publication-title: Neurol Neuroimmunol Neuroinflammation
– volume: 15
  start-page: 287
  year: 2019
  end-page: 300
  article-title: Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
  publication-title: Nat Rev Neurol
– volume: 141
  start-page: 585
  year: 2021
  end-page: 604
  article-title: Neuron-specific activation of necroptosis signaling in multiple sclerosis cortical grey matter
  publication-title: Acta Neuropathol
– volume: 83
  start-page: 739
  year: 2018
  end-page: 755
  article-title: Inflammatory intrathecal profiles and cortical damage in multiple sclerosis
  publication-title: Ann Neurol
– volume: 144
  start-page: 1384
  year: 2021
  end-page: 1395
  article-title: Cortical involvement determines impairment 30 years after a clinically isolated syndrome
  publication-title: Brain
– volume: 134
  start-page: 678
  year: 2011
  end-page: 692
  article-title: Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
  publication-title: Brain
– volume: 33
  start-page: 1444
  year: 1983
  end-page: 1452
  article-title: Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)
  publication-title: Neurology
– volume: 73
  start-page: 1914
  year: 2009
  end-page: 1922
  article-title: A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
  publication-title: Neurology
– volume: 91
  start-page: E153
  year: 2018
  end-page: E161
  article-title: Fingolimod vs dimethyl fumarate in multiple sclerosis a real-world propensity score-matched study
  publication-title: Neurology
– volume: 20
  start-page: 304
  year: 2014
  end-page: 312
  article-title: Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration
  publication-title: Mult Scler
– volume: 391
  start-page: 1622
  year: 2018
  end-page: 1636
  article-title: Multiple sclerosis
  publication-title: Lancet
– volume: 294
  start-page: 1731
  year: 2001
  end-page: 1735
  article-title: The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
  publication-title: Science
– volume: 23
  start-page: 1179
  year: 2017
  end-page: 1187
  article-title: ‘No evident disease activity’: the use of combined assessments in the management of patients with multiple sclerosis
  publication-title: Multi Scler
– volume: 11
  start-page: 1082
  year: 2012
  end-page: 1092
  article-title: Measurement and clinical effect of grey matter pathology in multiple sclerosis
  publication-title: Lancet Neurol
– volume: 283
  start-page: 64
  year: 2015
  end-page: 69
  article-title: Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis
  publication-title: J Neuroimmunol
– volume: 205
  start-page: 24
  year: 2000
  end-page: 33
  article-title: Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG35-55-induced experimental autoimmune encephalomyelitis
  publication-title: Cell Immunol
– volume: 83
  start-page: 278
  year: 2014
  end-page: 286
  article-title: Defining the clinical course of multiple sclerosis: the 2013 revisions
  publication-title: Neurology
– volume: 143
  start-page: 3013
  year: 2020
  end-page: 3024
  article-title: Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
  publication-title: Brain
– volume: 14
  start-page: 190
  year: 2020
  article-title: Connecting immune cell infiltration to the multitasking microglia response and TNF receptor 2 induction in the multiple sclerosis brain
  publication-title: Front Cell Neurosci
– volume: 17
  start-page: 162
  year: 2018
  end-page: 173
  article-title: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
  publication-title: Lancet Neurol
– volume: 367
  start-page: 1098
  year: 2012
  end-page: 1107
  article-title: Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
  publication-title: N Engl J Med
– volume: 20
  start-page: 653
  year: 2021 2021
  end-page: 670
  article-title: MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
  publication-title: Lancet Neurol
– volume: 13
  start-page: 227
  year: 1983
  end-page: 231
  article-title: New diagnostic criteria for multiple sclerosis: guidelines for research protocols
  publication-title: Ann Neurol
– volume: 92
  year: 2019
  article-title: Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
  publication-title: Neurology
– volume: 76
  start-page: 1474
  year: 2019
  end-page: 1483
  article-title: Association of chronic active multiple sclerosis lesions with disability in vivo
  publication-title: JAMA Neurol
– volume: 27
  start-page: 301
  year: 2017
  end-page: 312
  article-title: Cortical gray matter MR imaging in multiple sclerosis
  publication-title: Neuroimaging Clinics of North America
– volume: 19
  start-page: 336
  year: 2020
  end-page: 347
  article-title: Advances in oral immunomodulating therapies in relapsing multiple sclerosis
  publication-title: Lancet Neurol
– volume: 9
  year: 2020 2290
  article-title: Re-examining the role of TNF in MS pathogenesis and therapy
  publication-title: Cells
– volume: 10
  year: 2021 1712
  article-title: Changes in cerebrospinal fluid balance of TNF and TNF receptors in naïve multiple sclerosis patients: early involvement in compartmentalised intrathecal inflammation
  publication-title: Cells
– ident: bibr10-17562864221092124
  doi: 10.1212/WNL.33.11.1444
– ident: bibr12-17562864221092124
  doi: 10.1177/1352458517703193
– ident: bibr16-17562864221092124
  doi: 10.1016/S1474-4422(12)70230-2
– ident: bibr13-17562864221092124
  doi: 10.1212/WNL.0b013e3181c47cc2
– ident: bibr41-17562864221092124
  doi: 10.1001/jamaneurol.2019.2399
– ident: bibr24-17562864221092124
  doi: 10.1212/NXI.0000000000001083
– ident: bibr27-17562864221092124
  doi: 10.1186/s40478-020-00938-1
– ident: bibr19-17562864221092124
  doi: 10.1016/S1474-4422(19)30391-6
– ident: bibr35-17562864221092124
  doi: 10.1212/NXI.0000000000001059.
– ident: bibr29-17562864221092124
  doi: 10.1177/1352458513498128
– ident: bibr25-17562864221092124
  doi: 10.1186/s12974-019-1650-x
– ident: bibr30-17562864221092124
  doi: 10.3390/cells9102290
– ident: bibr34-17562864221092124
  doi: 10.1038/ni1415
– ident: bibr2-17562864221092124
  doi: 10.1212/WNL.0000000000000560
– ident: bibr39-17562864221092124
  doi: 10.1177/1352458515616701
– ident: bibr38-17562864221092124
  doi: 10.1212/01.wnl.0000435551.90824.d0
– ident: bibr9-17562864221092124
  doi: 10.1056/NEJMoa1114287
– ident: bibr18-17562864221092124
  doi: 10.1001/jamaneurol.2018.4905
– ident: bibr37-17562864221092124
  doi: 10.1093/brain/aws246
– ident: bibr42-17562864221092124
  doi: 10.1212/WNL.0000000000007032
– ident: bibr3-17562864221092124
  doi: 10.1016/S1474-4422(17)30470-2
– ident: bibr33-17562864221092124
  doi: 10.1126/science.1062960
– ident: bibr36-17562864221092124
  doi: 10.1001/jamaneurol.2014.3537
– ident: bibr20-17562864221092124
  doi: 10.1038/s41582-019-0170-8
– ident: bibr6-17562864221092124
  doi: 10.1002/ana.25786
– ident: bibr14-17562864221092124
  doi: 10.1002/ana.25197
– ident: bibr7-17562864221092124
  doi: 10.1212/NXI.0000000000001082.
– ident: bibr31-17562864221092124
  doi: 10.1006/cimm.2000.1706
– ident: bibr17-17562864221092124
  doi: 10.1016/j.neuroimage.2012.01.021
– ident: bibr15-17562864221092124
  doi: 10.1016/j.nic.2016.12.009
– ident: bibr22-17562864221092124
  doi: 10.1212/WNL.0000000000005772
– ident: bibr4-17562864221092124
  doi: 10.1212/WNL.0000000000005685
– ident: bibr5-17562864221092124
  doi: 10.1093/brain/awaa251
– ident: bibr40-17562864221092124
  doi: 10.1093/brain/awab033
– ident: bibr11-17562864221092124
  doi: 10.1002/ana.410130302
– ident: bibr26-17562864221092124
  doi: 10.3389/fncel.2020.00190
– ident: bibr21-17562864221092124
  doi: 10.1016/j.jneuroim.2015.04.011
– ident: bibr32-17562864221092124
  doi: 10.1007/s00401-021-02274-7
– ident: bibr8-17562864221092124
  doi: 10.1093/brain/awq386
– ident: bibr23-17562864221092124
  doi: 10.1111/ene.13272
– ident: bibr28-17562864221092124
  doi: 10.3390/cells10071712
– ident: bibr43-17562864221092124
  doi: 10.1016/S1474-4422(21)00095-8
– ident: bibr1-17562864221092124
  doi: 10.1016/S0140-6736(18)30481-1
SSID ssj0062740
Score 2.3122244
Snippet Background: Disease activity in the first years after a diagnosis of relapsing-remitting multiple sclerosis (RRMS) is a negative prognostic factor for...
Background: Disease activity in the first years after a diagnosis of relapsing-remitting multiple sclerosis (RRMS) is a negative prognostic factor for...
Disease activity in the first years after a diagnosis of relapsing-remitting multiple sclerosis (RRMS) is a negative prognostic factor for long-term...
SourceID doaj
pubmedcentral
proquest
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 17562864221092124
SubjectTerms APRIL protein
CD163 antigen
Cerebrospinal fluid
Chemokines
CXCL12 protein
CXCL13 protein
Demography
Diagnosis
Inflammation
Interleukin 12
Ligands
Lymphocytes B
Magnetic resonance imaging
Multiple sclerosis
Original Research
Osteopontin
Patients
Substantia alba
Substantia grisea
Tumor necrosis factor
Tumor necrosis factor-TNF
Tumors
γ-Interferon
SummonAdditionalLinks – databaseName: Publicly Available Content Database
  dbid: PIMPY
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFA46K7Iv3mWrq0QQBKFsN0lzeRJdHBTcYcAV1qeS5qKDQztOZwX_vee06ayjuE--NglJepKTL8nJ9xHynDlTxGCK3AqhclHDlKq9t7lRsfDMR6YGntkPajbT5-dmnp5HdymscvSJvaMe2J4xbhuc8JFvHZ6YHzGlDOw8jOavVt9z1JDCu9YkqHGd7CHxlp6Qvfn70_nn0TOjzMzwQLKUOdOlTLecSMCE35gGMA5bIAPuXOysUz2d_w4G_TOC8rcwsH5lmt7-v326Q24lhEpfD0PqLrkWmnvk5mm6g79Pvp18nNKz2ZTaxlN8ItKuWpSboEuMP-qoQ72PJUBYime8FAAmXQ-BuIFuWuoXKFr9c0kjBndjNigakGaZjsGNtIOK4a8sugfk0_Tt2cm7PEk25A6QxyYHb-WCC0IBrONRWsa9tq5WIQgtTfQiMBNLE7WMHtVlvOKwIHLnirrWnNf8IZk0bRMOCGXSA7yrrXaRC-8B2ZaOlUFypq0suMtIMRqoconPHGU1ltVxojD_y6YZebktshrIPK7K_Aatvs2IPNz9h3b9pUrTugreQ9uPoRulB2jnrPFCyWjKWJbOFjojh6Plq-QcuurS0Bl5tk2GaY13NbYJ7QXkkRq2ugLgWkbUzljbadBuSrP42hOEG9y3cyj5AkflZcX_7Oujq5v5mOwzfPXRnzwdkslmfRGekBvux2bRrZ-mWfYLncw0Fw
  priority: 102
  providerName: ProQuest
Title CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis
URI https://journals.sagepub.com/doi/full/10.1177/17562864221092124
https://www.proquest.com/docview/2779156983
https://www.proquest.com/docview/2681444190
https://pubmed.ncbi.nlm.nih.gov/PMC9218430
https://doaj.org/article/eddcc01d735d439ca9d476f95f55ca08
Volume 15
WOSCitedRecordID wos000814448400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1756-2864
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062740
  issn: 1756-2864
  databaseCode: DOA
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1756-2864
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062740
  issn: 1756-2864
  databaseCode: 7X7
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1756-2864
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062740
  issn: 1756-2864
  databaseCode: BENPR
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1756-2864
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062740
  issn: 1756-2864
  databaseCode: PIMPY
  dateStart: 20160101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEB_0FPFF_MTquUQQBKHYS9ImefSOWxS8ZdET1qeS5gMXl_bY7gn-9870Y70q6osvhbYJTSaTzG-ayW8AXnBnshhMllopVSornFKV9zY1Kmae-8hVzzP7Xi0WerUyyyupvigmrKcH7gX3OnjvXHbklcg9Gk9njZeqiCaPee5sf8wXUc_oTPVrMCWUGfcwiV4JbSQdwZQcHRyDi7WcWKGOrH-CMH-Nj7wS5NXZnflduDMARvamb-g9uBbq-3DrbNgSfwBfTz7O2flizmztGZ3YaC4ayv7ANhQO1DJH6Tc2iCgZ_XJliPfYto-LDWzXML-mHNLfNyxSrDUVw6qBWI_ZGGvIWvwwdmPdPoRP89Pzk7fpkEEhdQgEdikuHi64IBWiLBELy4XX1lUqBKkLE70M3MTcRF1ET8leUMponwQKvKq0EJV4BAd1U4fHwHjhEW1VVrsopPco8tzxPBSCa1tkwiWQjRIt3UAvTlkuNuXRwCj-2yAk8Gpf5aLn1vhb4WMapn1BosXuHqCylIOylP9SlgQOx0Euh7nallwpg16s0SKB5_vXOMto68TWobnEMoVGz1MiekpATZRj0qDpm3r9pePrNuRGC6z5ktTo54f_2Ncn_6OvT-E2p6Ma3e-iQzjYbS_DM7jpvu3W7XYG19VKdVc9gxvHp4vlh1k3hfBu-e5s-fkH_MYdAw
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgigX3ohAASOBkJAiUjuJ7QNCUFi16naFxCLtLU38oCtWybLZgvqn-I3M5LFlQfTWA1fHTmxnZvyNPZ4P4Bk3OvJOR2EexzKMC1Spwto81NJHllvPZZtndihHIzWZ6I8b8LO_C0Nhlb1NbAy1rQztkb_iUmr0NbQSb-bfQmKNotPVnkKjFYsDd_oDXbb69f57_L_POR98GO_uhR2rQGhwcVyGqFDGGRdLRB7CpzkXVuWmkM7FKtXexo5rn2ivUm-JAMVKgTZbGBMVhRKiEPjeS3AZyySFkMnJysEjGpv2AmaShlwlaXeKSgmeqIwrBPvoYmlcLuK1dbChC1jDuH9GaP4WZtasfIMb_9uc3YTrHcZmb1uluAUbrrwNVw-7KII78HX304CNRwOWl5bRJZdqXhFhBptRBFXNDDGWzBCEM9qlZgiR2aINJXZsWTE7Jdrt0xnzFJ5O1bCpo0TRrA_PZDV-GOd9Wt-Fzxcy1HuwWValuw-MpxYBapEr40VsLWLzxPDEpYKrPI2ECSDqRSAzXUZ2IgaZZTtdEva_pCaAl6sm8zYdyXmV35FcrSpSJvGmoFp8yTrDlDlrse87OIzEIjg1ubaxTL1OfJKYPFIBbPeylXXmrc7OBCuAp6vHaJjotCkvXXWCdVKFznqMgDMAuSbNax1af1JOj5sU55p2HgS2fEFyf_bhf471wfndfAJbe-PDYTbcHx08hGuc7rA0-2jbsLlcnLhHcMV8X07rxeNGoxkcXbQ6_ALrAoSO
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CSF+TNF+and+osteopontin+levels+correlate+with+the+response+to+dimethyl+fumarate+in+early+multiple+sclerosis&rft.jtitle=Therapeutic+advances+in+neurological+disorders&rft.au=Damiano+Marastoni&rft.au=Anna+I.+Pisani&rft.au=Gianmarco+Schiavi&rft.au=Valentina+Mazziotti&rft.date=2022&rft.pub=SAGE+Publishing&rft.eissn=1756-2864&rft.volume=15&rft_id=info:doi/10.1177%2F17562864221092124&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_eddcc01d735d439ca9d476f95f55ca08
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-2864&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-2864&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-2864&client=summon